Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab Rechallenge in mCRC (CHRONOS)
NCT03227926Phase 2Completed
- Sponsor
- Fondazione del Piemonte per l'Oncologia
- Start
- Oct 2017
- Primary completion
- Nov 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in metastatic colorectal cancer (mCRC), sponsored by Fondazione del Piemonte per l'Oncologia. Primary endpoint: Overall Response Rate at 48 months. Started Oct 2017; status: completed.
02
Drugs
panitumumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03227926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03227926.